IGF1 and Hypoglycemia: Sitagliptin is extensively used for type 2 diabetes treatment, exhibiting a low risk of hypoglycemia with minimal side effects through oral administration.[21, 22] Nonetheless, concerns remain regarding oral sitagliptin administration for scar treatment, including insufficient local concentrations in the skin and treatment‐related risks for non‐diabetic individuals.[52] To address these issues, we utilized the recently established[36] hydrogel MNP system to deliver sitagliptin or IGF1 directly into the wound bed, achieving a sustained, localized therapy.